Poor
Mostly Aligned
Patient Risk:
Moderate
Summary
Many statements about Vascepa’s indication/mechanism and some bleeding/monitoring concepts are broadly consistent with the label, but multiple interaction claims (omega-6, flaxseed oil, sunflower oil, vitamin E, ginkgo, St. John’s Wort, garlic, and omega-3 supplement avoidance) are not supported by the provided prescribing information excerpts. Several claims overgeneralize or add unsupported guidance to avoid specific non-labeled substances.
Category Scores
Accurate Statements
Vascepa (icosapent ethyl) is a prescription medication used to lower triglyceride levels in the blood.
Supported generally by the label indication to reduce TG levels in adults with severe hypertriglyceridemia (1 INDICATIONS AND USAGE).
Aspirin can increase the risk of bleeding when taken with Vascepa.
Supported: incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, and the label advises monitoring with anticoagulants/antiplatelet agents for bleeding (5.3; 7.1).
Warfarin can interact with Vascepa, increasing the risk of bleeding.
Supported: bleeding incidence greater with concomitant antithrombotic medications such as warfarin; monitor patients receiving VASCEPA with anticoagulants and/or antiplatelet agents (5.3; 7.1).
Patients taking aspirin and Vascepa should be monitored closely for signs of bleeding.
Supported by the label’s recommendation to monitor patients receiving VASCEPA and concomitant anticoagulants and/or antiplatelet agents for bleeding (7.1) and increased bleeding risk with concomitant antithrombotics (5.3).
Patients taking warfarin and Vascepa should be closely monitored by their healthcare provider.
Supported by monitoring guidance for patients on concomitant anticoagulants (7.1) and increased bleeding with warfarin (5.3).
Flaxseed oil is high in omega-6 fatty acids that can counteract the effects of Vascepa.
Not supported by the provided label excerpts.
Unsupported Statements
Vascepa is used to lower triglyceride levels in the blood in individuals with high triglyceride levels.
The label specifies particular indications/populations (adjunct to statin for CV risk reduction with elevated TG; and adjunct to diet to reduce TG in severe hypertriglyceridemia). The claim is overly broad relative to the label excerpts.
Vascepa inhibits the production of triglycerides in the liver.
The label mechanism states studies suggest EPA reduces hepatic VLDL-TG synthesis and/or secretion and enhances TG clearance; it does not state this as an unequivocal effect of Vascepa inhibiting triglyceride production in the liver (12.1).
EPA has anti-inflammatory properties that can help reduce the risk of cardiovascular disease.
No anti-inflammatory claim is present in the provided label excerpts.
Flaxseed oil is high in omega-6 fatty acids that can counteract the effects of Vascepa.
No omega-6/flaxseed oil dietary interaction guidance is present in the provided label excerpts.
Omega-6 fatty acids can increase inflammation, which can negate the anti-inflammatory effects of Vascepa.
Not supported by the provided label excerpts.
Sunflower oil can interact with Vascepa.
No sunflower oil interaction is described in the provided label excerpts.
Patients taking Vascepa should avoid consuming large amounts of sunflower oil.
Not supported by the provided label excerpts.
High doses of vitamin E can increase the risk of bleeding when taken with Vascepa.
No vitamin E dosing-specific bleeding interaction is described in the provided label excerpts.
Patients taking high doses of vitamin E and Vascepa should be closely monitored by their healthcare provider.
Not supported by the provided label excerpts.
Ginkgo biloba can increase the risk of bleeding when taken with Vascepa.
No ginkgo biloba interaction is described in the provided label excerpts.
Patients taking ginkgo biloba and Vascepa should be closely monitored by their healthcare provider.
Not supported by the provided label excerpts.
St. John's Wort can interact with Vascepa, increasing the risk of bleeding.
No St. John’s Wort interaction is described in the provided label excerpts.
Patients taking St. John's Wort and Vascepa should be closely monitored by their healthcare provider.
Not supported by the provided label excerpts.
Garlic supplements can increase the risk of bleeding when taken with Vascepa.
No garlic interaction is described in the provided label excerpts.
Patients taking garlic supplements and Vascepa should be closely monitored by their healthcare provider.
Not supported by the provided label excerpts.
Patients taking Vascepa should avoid consuming large amounts of omega-6 fatty acids.
Not supported by the provided label excerpts.
Patients taking Vascepa should avoid taking high doses of vitamin E supplements.
Not supported by the provided label excerpts.
Patients taking Vascepa should avoid taking ginkgo biloba supplements.
Not supported by the provided label excerpts.
Patients taking Vascepa should avoid taking St. John's Wort supplements.
Not supported by the provided label excerpts.
Patients taking Vascepa should avoid taking garlic supplements.
Not supported by the provided label excerpts.
Patients taking Vascepa should be closely monitored by their healthcare provider for signs of bleeding or other adverse effects.
The label specifically recommends monitoring for bleeding when combined with anticoagulants/antiplatelet agents (7.1). Broad monitoring for 'other adverse effects' is not supported by the provided excerpts.
Patients taking Vascepa should consult with their healthcare provider before taking other medications, as certain interactions can increase the risk of bleeding or exacerbate cardiovascular disease.
Label excerpts support bleeding risk with anticoagulants/antiplatelet agents (5.3; 7.1) but do not support exacerbation of cardiovascular disease as an interaction consequence.
Patients taking Vascepa should avoid taking omega-3 supplements because they can interact with Vascepa and increase the risk of bleeding.
No omega-3 supplement avoidance guidance is present in the provided label excerpts.
Patients taking Vascepa should avoid taking ginkgo biloba supplements because they can increase the risk of bleeding.
Not supported by the provided label excerpts.
Patients taking Vascepa should avoid taking high doses of vitamin E supplements because they can increase the risk of bleeding.
Not supported by the provided label excerpts.
Patients taking Vascepa should avoid taking St. John's Wort supplements because they can interact with Vascepa and increase the risk of bleeding.
Not supported by the provided label excerpts.
Contradictions
Important Omissions
The label’s specific indication details (adjunct to maximally tolerated statin to reduce risk of MI/stroke/etc. in adults with elevated TG meeting stated criteria; and adjunct to diet to reduce TG in severe hypertriglyceridemia) are not reflected in the TG-lowering claims, which are overly general.
Importance:
Moderate
The label describes increased risk of atrial fibrillation/atrial flutter with VASCEPA; none of the provided claims mention this warning.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported interaction/avoidance advice could mislead patients about specific supplements (omega-6, flaxseed/sunflower oil, vitamin E, ginkgo, St. John’s Wort, garlic, omega-3 supplements). While the bleeding-risk-with-aspirin/warfarin concept aligns with the label, the breadth of unsupported guidance increases the risk of misinformation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Major portions of the drug interaction/dietary supplement avoidance list are not supported by the provided prescribing information excerpts.
Suggested Improvement
Limit interaction/monitoring statements to those explicitly supported: increased bleeding risk with concomitant antithrombotic medications (e.g., aspirin, clopidogrel, warfarin) and general monitoring for bleeding when used with anticoagulants/antiplatelet agents. Remove or rephrase unsupported claims about omega-6/flaxseed/sunflower oil, vitamin E, ginkgo biloba, St. John’s Wort, garlic, and omega-3 supplement avoidance unless supported by the label.